This was a retrospective, observational, comparative cohort study using secondary data from electronic health records (EHR) from a local health unit that provides primary, secondary and tertiary care to a resident population in northern Portugal. The study aimed to assess the comparative effectiveness of sacubitril/valsartan (SAC/VAL) versus angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients with heart failure with reduced ejection fraction (HFrEF).
Study Type
OBSERVATIONAL
Enrollment
1,249
Novartis
East Hanover, New Jersey, United States
Hazard Ratio for the Composite of Cardiovascular Death or Heart Failure Hospitalization
Time frame: 180 days, 810 days, 1260 days
Hazard Ratio for Death From Cardiovascular Causes
Time frame: 180 days, 810 days, 1260 days
Hazard Ratio for Hospitalization for Heart Failure
Time frame: 180 days, 810 days, 1260 days
Hazard Ratio for First Hospitalization or Emergency Room Visit
Hospitalizations or emergency room visits for heart failure, and any cause were recorded.
Time frame: 180 days, 810 days, 1260 days
Hazard Ratio for First Cardiovascular-specific Hospitalization
Time frame: 180 days, 810 days, 1260 days
Hazard Ratio for the Composite of Death From Cardiovascular Causes, Hospitalization for Heart Failure, Non-fatal Myocardial Infarction and Non-fatal Stroke
Time frame: 180 days, 810 days, 1260 days
Hazard Ratio for Implantable Cardioverter-defibrillator (ICD) Procedure
Time frame: 180 days, 810 days, 1260 days
Hazard Ratio for All-cause Mortality
Time frame: 180 days, 810 days, 1260 days
Hazard Ratio for Improved LVEF
Improved LVEF was defined as having at least one LVEF measurement equal or above 40% after having an LVEF under 40%.
Time frame: 180 days, 810 days, 1260 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pearson Correlation Coefficient Between Change From Baseline in NT-proBNP and LVEF
Time frame: 180 days, 810 days, 1260 days
Change From Baseline in NT-proBNP
Time frame: 180 days, 810 days, 1260 days
Change From Baseline in LVEF
Time frame: 180 days, 810 days, 1260 days
Total Healthcare Resource Utilization Costs per Calendar Year
Healthcare utilization costs included costs for inpatient care, outpatient care, medication, and exams.
Time frame: Up to 5 years
Number of Days Patients Were Absent From Work per Calendar Year
Time frame: Up to 5 years
Healthcare Resource Utilization Costs per Patient per Year
Healthcare utilization costs included costs for inpatient care, outpatient care, medication, and exams.
Time frame: Up to 5 years
Hazard Ratio for Hyperkalemia
Time frame: 180 days, 810 days, 1260 days
Rate of Dose Titration Events per 100-Person-Years
Rates were measured for dose titrations from: * low to medium * medium to low * medium to high * high to medium
Time frame: 180 days, 810 days, 1260 days
Rate of Patients Reaching the Maximum Dose per 100-Person-Years
Time frame: 180 days, 810 days, 1260 days
Rate of Treatment Discontinuation
Time frame: 180 days, 810 days, 1260 days
Number of Patients by Demographic Category
Demographics included age and sex.
Time frame: Baseline
Number of Patients by Clinical Characteristic Category
Clinical characteristics included: * New York Heart Association (NYHA) Class * eGFR ≥ 60 mL/minute/1.73 m\^2 * eGFR \< 60 mL/minute/1.73 m\^2 * LVEF ≤ 35% * LVEF \> 35% * Type of medication * Comorbidities
Time frame: Baseline